Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer

NCT04117945 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

22

Enrollment

OTHER

Sponsor class

Conditions

BRAF V600E Negative
KRAS Gene Mutation Negative
Locally Advanced Unresectable Colorectal Adenocarcinoma
Metastatic Colorectal Adenocarcinoma
NRAS Gene Mutation Negative
Stage III Colorectal Cancer AJCC v8
Stage IIIA Colorectal Cancer AJCC v8
Stage IIIB Colorectal Cancer AJCC v8
Stage IIIC Colorectal Cancer AJCC v8
Stage IV Colorectal Cancer AJCC v8
Stage IVA Colorectal Cancer AJCC v8
Stage IVB Colorectal Cancer AJCC v8
Stage IVC Colorectal Cancer AJCC v8

Interventions

BIOLOGICAL: Cetuximab
DRUG: Irinotecan
BIOLOGICAL: Panitumumab
DRUG: Regorafenib

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]